Terapêutica disponível para a Doença hepática gordurosa não alcoólica e sua relação com a evolução do diabetes melito tipo 2: uma revisão de literatura / Available therapy for non-alcoholic fatty liver disease and its relationship with the evolution of type 2 diabetes mellitus: a literature review

Diego Handeri Hermes, Sersie Lessa Antunes Costa Almeida, Alice Faria Santos Fernandes, Diogo Ordones Delfraro, Helena Ribeiro de Oliveira, João Pedro Pereira, Lorena Galdino Teixeira, Matheus Victor Pereira, Natália de Azevedo Marques, Priscilla da Cunha Leal, João Paulo da Rocha Santos

Abstract


INTRODUÇÃO: A doença hepática gordurosa não alcoólica (DHGNA) é uma das principais causas de insuficiência hepática, hepatocarcinoma e transplante de fígado. Devido aos eventos que levam à sua evolução, torna-se essencial elucidar seus fatores de risco, a fim de instituir a prevenção de suas complicações. Um importante fator conhecido é o Diabetes Mellitus Tipo 2 (DM2) e, portanto, o objetivo deste artigo é discutir a correlação entre DHGNA e DM2 e seus tratamentos. RESULTADOS: A análise das informações demonstrou a diabetes como o principal fator de risco para o desenvolvimento da DHGNA e se estabeleceu como a melhor terapêutica disponível a perda de peso e o uso de tiazolidinedionas. DISCUSSÃO: A resistência insulínica e a DHGNA estão bidirecionalmente relacionadas. Dessa forma, a perda de peso e o uso de antidiabéticos são as principais formas encontradas para que haja um melhor prognóstico para o paciente. CONCLUSÃO: O diagnóstico precoce da DHGNA é imprescindível, objetivando estabelecer a melhor conduta clínica frente ao paciente. A detecção dos fatores de risco é indispensável para que se saiba indicar o tratamento ideal, entre os quais se destacam a perda de peso e o uso de antidiabéticos orais.


Keywords


Doença hepática gordurosa não alcoólica, Diabetes Mellitus Tipo II, Antidiabéticos, Perda de Peso.

References


ANDRADE, G.C., et al. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras, v. 62, n 3. p. 218-226, 2016.

Bifari F; et al. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research, v. 137, 2018.

DHARMALINGAM, M; YAMASANDHI, P.G. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab, v. 22, n 3. p. 421–428, 2018.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obesity facts. 2016.

FERREIRA, V.S.G., et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metab, v. 54, n 4. p. 362-368, 2010.

GIESTAS, S. , et al. Liver Disease and Diabetes Mellitus – A Bi-Directional Relation. Revista Portuguesa de Diabetes. v.10, n 4. p. 158-166, 2015.

Grosso G.; et al. Mediterranean diet and cardiovascular risk factors: a systematic review. Critical Reviews in Food Science and Nutrition, v. 54, n.5, 2013.

Harrison S, et al. Non-Alcoholic Steatohepatitis Effect of Roux-en-Y Gastric Bypass Surgery. American Journal Gastroenterology, v. 101, n 2. p. 368-373, 2006

He, L., et al. Thiazolidinediones for nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials. Medicine, v. 95, n 42, 2016.

Jarvis H; et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. Public Library of Science Medicine, v. 17, n 4, 2020.

Kenneally, S., et al. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterology, v. 4, n 1, 2017.

Koopman K.E.; et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Journal of Hepatology, v.60, n.2, 2014.

Lallukka S Yki. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best practice and research. Clinical endocrinology and metabolism, v. 30, n 3, 2016.

Mantovani A, et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab DIABET-101142; No. of Pages 15, 2020.

Mantovani A, et al. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Diabetes Journals, v. 41, p. 372-382, 2018

Marchisello, S., et al. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. International Journal of Molecular Sciences, v. 20, n 8. p. 1948, 2019.

OTT-FONTES, P.R., et al. Comparison of the severity of non-alcoholic fatty liver disease in diabetic and non-diabetic obese patients. Rev. Col. Bras. Cir. v.47. Rio de Janeiro, 2020

Rahmanabadi A, et al. Oral α-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: effects on adipokines and liver histology features. Food Funct. 2019;10(8):4941-4952.

Raj H, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World Journal of Diabetes, v. 10, n. 2, 2019.

Ratziu, V., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology, v. 135, n 1. p. 100-110, 2008.

Snowling N.J; et al. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta analysis. Diabetes Care, 2006.

Tang W., et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes/Metabolism Research and Reviews, v. 32, 2016.

Tilg, H.; Moschen, A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol e Dietologica, v. 56, n 2. p. 159-167, 2010.

Uusitupa, M. A. Lifestyle changes and cardiovascular risk reduction in diabetes.The lancet, v.4, n.11, 2016.

Velasco, J. V. R., et al. Extrahepatic complications of non-alcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition), v. 84, n 4. p. 472-481, 2019.

Younossi, Z. M.; et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, v. 64, n. 1, p. 73-84, 2016.

Zelber-Sagi, S., et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. Journal of Hepatology, v. 56, n 5. p. 1145-51, 2012.




DOI: https://doi.org/10.34119/bjhrv3n4-364

Refbacks

  • There are currently no refbacks.